Buy Zenas (ZBIO): Obexelimab Workflow Reset and SLE Data Could Re-rate the Stock
Zenas BioPharma is a high-conviction long because management has secured new financing, is preparing a BLA filing for obexelimab, and expects Phase 2 lupus data by year-end 2026. The market has punished the stock after a disappointing IgG4-RD Phase 3 readout, leaving upside if obexelimab shows meaningful activity in SLE or if the FDA engagement aro…